TNF and Alzheimer disease: The level of TNF-α was decreased in groups receiving β-asarone (20 mg/kg, 30 mg/kg) treatment compared to the AD model group (189.8 ± 42.12 versus 239.8 ± 30.89 pg/Ml, 174.0 ± 48.28 versus 239.8 ± 30.89 pg/mL, P < 0.05, P < 0.01).